| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
113,340,000 |
| Market
Cap: |
126.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6758 - $2.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
| Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
245,339 |
267,139 |
312,283 |
979,563 |
| Total Sell Value |
$289,577 |
$316,630 |
$384,544 |
$4,272,335 |
| Total People Sold |
6 |
6 |
6 |
8 |
| Total Sell Transactions |
17 |
22 |
34 |
59 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kauffman Michael |
Chief Executive Officer |
• • – |
2019-11-11 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
539,767 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-11-08 |
4 |
AS |
$14.63 |
$146,254 |
D/D |
(10,000) |
731,134 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-11-08 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
741,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-11-08 |
4 |
AS |
$14.63 |
$146,254 |
I/I |
(10,000) |
731,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-11-08 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
741,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-11-01 |
4 |
AS |
$12.00 |
$120,000 |
I/I |
(10,000) |
731,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-11-01 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
741,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-11-01 |
4 |
AS |
$12.00 |
$120,000 |
D/D |
(10,000) |
529,767 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-11-01 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
539,767 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-11-01 |
4 |
AS |
$12.00 |
$120,000 |
I/I |
(10,000) |
529,767 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-11-01 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
539,767 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-11-01 |
4 |
AS |
$12.00 |
$120,000 |
D/D |
(10,000) |
731,134 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-11-01 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
741,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-09-16 |
4 |
AS |
$12.00 |
$120,000 |
I/I |
(10,000) |
731,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-09-16 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
741,134 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-09-16 |
4 |
AS |
$12.00 |
$120,000 |
D/D |
(10,000) |
529,767 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2019-09-16 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
539,767 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-09-16 |
4 |
AS |
$12.00 |
$120,000 |
I/I |
(10,000) |
529,767 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-09-16 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
539,767 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-09-16 |
4 |
AS |
$12.00 |
$120,000 |
D/D |
(10,000) |
731,134 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2019-09-16 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
741,134 |
|
- |
|
| Shah Jatin |
EVP, Chief Medical OfficerOffi |
• – – |
2019-07-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
34,625 |
|
- |
|
| Smolokowski Wiaczeslaw |
10% Owner |
– – • |
2019-02-28 |
4 |
S |
$4.14 |
$619,114 |
D/D |
(149,624) |
6,000,000 |
|
- |
|
| Smolokowski Wiaczeslaw |
10% Owner |
– – • |
2019-02-27 |
4 |
S |
$4.51 |
$2,515,834 |
D/D |
(558,243) |
6,149,624 |
|
- |
|
| Smolokowski Wiaczeslaw |
10% Owner |
– – • |
2019-02-26 |
4 |
S |
$5.00 |
$617,210 |
D/D |
(123,400) |
6,707,867 |
|
- |
|
592 Records found
|
|
Page 13 of 24 |
|
|
0.02 (1.75%) 
